Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02754440 · ClinicalTrials.gov registry record · NA
Evaluation of Trima Version 7.0 Platelets in PAS
A NA study, sponsored by Terumo BCT.
- Completed
- Registry status
- NA
- Development phase
- 365
- Enrollment target
NCT02754440: Completed NA study, sponsored by Terumo BCT.
NCT02754440 is a NA study that has completed, run by Terumo BCT. The registered enrollment target is 365 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02754440, a NA study, has completed, sponsored by Terumo BCT.
- COMPLETED
- Registry status
- NA
- Development phase
- 365 participants
- Enrollment target
Study Summary
To verify that platelets collected on the Trima Accel system with Version 7.0 software enhancements and stored in platelet additive solution (PAS) meet the FDA requirements for leukoreduction (\< 5.0 × 10\^6 residual white blood cells \[WBC\] per transfusable unit).
Primary Outcome
The number of participants with platelet units containing an acceptable residual WBC level. Acceptable residual WBC counts are: singles = residual WBC level \< 5.0 × 10\^6; doubles = residual WBC level \< 8.0 × 10\^6 or \< 5.0 × 10\^6 for each transfusable unit; and triples = residual WBC level \< 12.0 × 10\^6 or \< 5.0 × 10\^6 for each transfusable unit.
Interventions
- DEVICE Trima Accel System with Version 7.0 Software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2016-04-20 |
| Est. Completion | 2017-07-28 |
| Phase | NA |
What the finished NCT02754440 record still lists
NCT02754440 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Trima Accel System with Version 7.0 Software is the first listed.
NCT02754440 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02754440 about?
NCT02754440 is a clinical study titled "Evaluation of Trima Version 7.0 Platelets in PAS". To verify that platelets collected on the Trima Accel system with Version 7.0 software enhancements and stored in platelet additive solution (PAS) meet the FDA requirements for leukoreduction (\< 5.0 × 10\^6 residual white blood cells \[WBC\] per transfusable unit).
What is the current status of trial NCT02754440?
This trial is currently completed. It is a NA study. The enrollment target is 365 participants. The study started on 2016-04-20. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT02754440?
The interventions under investigation include: Trima Accel System with Version 7.0 Software (DEVICE).
Who is sponsoring clinical trial NCT02754440?
This trial is sponsored by Terumo BCT, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02754440's enrollment target sits among peer trials
365 284th of 2000 higher than 1,717 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI